A Phase 2 Study of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Diet and Exercise

PHASE2CompletedINTERVENTIONAL
Enrollment

113

Participants

Timeline

Start Date

March 31, 2022

Primary Completion Date

January 17, 2023

Study Completion Date

January 17, 2023

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

HTD1801

HTD1801 administered orally BID as two capsules

DRUG

Placebo

Matching placebo administered orally BID as two to four capsules

DRUG

HTD1801

HTD1801 administered orally BID as four capsules

Trial Locations (14)

Unknown

Peking University People's Hospital, Beijing

The Second Hospital of Jilin University, Changchun

The First People's Hospital of Changde City, Changde

The Fourth Affiliated Hospital of Harbin Medical University, Harbin

Huizhou Municipal Central Hospital, Huizhou

Jinan Central Hospital, Jinan

Liaocheng People's Hospital, Liaocheng

The First Affiliated Hospital of Henan University of Science and Technology, Luoyang

Nanjing First Hospital, Nanjing

Nanjing Jiangning Hospital, Nanjing

Sir Run Run Hospital Nanjing Medical University, Nanjing

The First Affiliated Hospital of Nanyang Medical College, Nanyang

Yan'an University Affiliated Hospital, Yanan

Affiliated Hospital of Jiangsu University, Zhenjiang

All Listed Sponsors
collaborator

Shenzhen HighTide Biopharmaceutical Ltd.

UNKNOWN

lead

HighTide Biopharma Pty Ltd

INDUSTRY